The Noradrenaline Metabolite MHPG Is a Candidate Biomarker from the Manic to the Remission State in Bipolar Disorder I: A Clinical Naturalistic Study

Autor: Yoshiro Okubo, Satoshi Nishino, Yukio Numata, Masatake Kurita, Tadahiro Sato
Rok vydání: 2014
Předmět:
Male
Bipolar Disorder
Lithium (medication)
lcsh:Medicine
Biochemistry
Severity of Illness Index
Methoxyhydroxyphenylglycol
Behavioral Neuroscience
Norepinephrine
chemistry.chemical_compound
Medicine and Health Sciences
Medicine
lcsh:Science
Chlorpromazine
Chromatography
High Pressure Liquid
Multidisciplinary
Remission Induction
Homovanillic acid
Neurochemistry
Middle Aged
Research Design
behavior and behavior mechanisms
Biomarker (medicine)
Female
Neurochemicals
medicine.symptom
Mania
Research Article
Antipsychotic Agents
medicine.drug
Adult
medicine.medical_specialty
Clinical Research Design
Neuropsychiatric Disorders
Enzyme-Linked Immunosorbent Assay
Research and Analysis Methods
Young Mania Rating Scale
behavioral disciplines and activities
Diagnostic Medicine
Internal medicine
Mental Health and Psychiatry
mental disorders
Humans
Bipolar disorder
Psychiatry
Retrospective Studies
Aged
Psychological and Psychosocial Issues
business.industry
Brain-Derived Neurotrophic Factor
lcsh:R
Biology and Life Sciences
Homovanillic Acid
Electrochemical Techniques
medicine.disease
Health Care
Endocrinology
Mood disorders
chemistry
lcsh:Q
business
Mental Health Therapies
Biomarkers
Neuroscience
Zdroj: PLoS ONE
PLoS ONE, Vol 9, Iss 6, p e100634 (2014)
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0100634
Popis: Remission is the primary goal of treatment for bipolar disorder I (BDI). Metabolites of noradrenaline and dopamine, 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA), respectively, are reduced by treatment with antipsychotics, but whether these phenomena are caused by antipsychotics or by the pathophysiology of BDI is not known. Interactions between brain-derived neurotrophic factor (BDNF) and mood disorders have also been suggested. We conducted a multifaceted study in BDI patients to ascertain if biological markers are associated with the manic state. Patients with Young Mania Rating Scale (YMRS) scores >20 participated in the study. Final analyses involved 24 BDI patients (13 men and 11 women). We used YMRS scores to identify mania stages in individual BDI patients (i.e., manic syndrome, response and remission stages). Statistical analyses were done using one-way repeated-measures analyses of variance (rep-ANOVA) throughout manic syndrome, response and remission stages. Plasma concentrations of MHPG and HVA were analyzed by high-performance liquid chromatography with electrochemical detection. Plasma levels of BDNF were measured by sandwich enzyme-linked immunosorbent assay. BDI patients had significantly reduced plasma levels of MHPG throughout manic syndrome, response and remission stages (rep-ANOVA, p = 0.002). Without a case of response state, there was a significant positive correlation between YMRS scores and plasma levels of MHPG (ρ = 0.33, p = 0.033, n = 48). Plasma levels of HVA and BDNF were not significantly altered throughout manic syndrome, response and remission stages. These data suggest that the peripheral level of MHPG (which is associated with noradrenaline levels in the brain) could be used as a biomarker for the manic state in BDI. The MHPG level is likely to reflect the clinical characteristics of the manic syndrome in BDI, and noradrenaline may reflect the pathophysiology from manic to remission states.
Databáze: OpenAIRE
Externí odkaz: